Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study

[1]  R. Ozols,et al.  Chemotherapy of ovarian cancer. , 1999, Seminars in oncology.

[2]  P. Zola,et al.  Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Tonato,et al.  Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. , 1996, American journal of clinical oncology.

[4]  P. Matarrese,et al.  Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. , 1995, Anticancer research.

[5]  G. Navon,et al.  Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. , 1995, Cancer research.

[6]  M. Martini,et al.  Combination of Epirubicin and Lonidamine for Treatment of Advanced Breast Cancer , 1995, Tumori.

[7]  F. Caponigro,et al.  Recovery of sensitivity to cisplatinum and epidoxorubicin by ionidamine and interferon in advanced ovarian-cancer. , 1994, International journal of oncology.

[8]  R. Franchi,et al.  Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast-cancer patients. , 1993, International journal of oncology.

[9]  R. Demicheli,et al.  Drugs ten years later: epirubicin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Marangolo,et al.  Conservative Treatment for T2-T4 Bladder Cancer with Primary Chemotherapy and Radiotherapy: A Pilot Study , 1993, Tumori.

[11]  N. Zaffaroni,et al.  Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells , 1992, International journal of cancer.

[12]  G. Zupi,et al.  Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. , 1991, British Journal of Cancer.

[13]  L. Dogliotti,et al.  Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist, ICS 205-930 , 1990, Tumori.

[14]  H. Wilke,et al.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Sledge,et al.  Cisplatin as first-line therapy for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Silvestrini,et al.  Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells. , 1987, Experimental and molecular pathology.

[17]  B. Silvestrini,et al.  In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. , 1986, Anticancer research.

[18]  B. Silvestrini,et al.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.

[19]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.

[20]  N. Nie,et al.  Statistical Package for the Social Sciences , 1970 .

[21]  A. Gadducci,et al.  Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. , 1994, European journal of cancer.

[22]  V. Lorusso,et al.  Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results , 1994 .

[23]  R. Stolfi,et al.  Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study , 1994 .

[24]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.